NEW YORK, October 14, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback